Navigation Links
Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose

Trial Convincingly Proves Functionality in Humans of CTI's Programmable, Pulsatile, Passive Transdermal Drug Delivery Device - ChronoDose

BASEL, Switzerland and TRENTON, N.J., May 03, 2007 /PRNewswire/ -- Chrono Therapeutics Inc. (CTI) announced today the successful completion of its first phase human clinical trial of its programmable, pulsatile, passive transdermal drug/device combination product: ChronoDose(TM). CTI intends to publish this clinical data in leading scientific and medical journals by year end.

CLINICAL STUDY DESIGN

The trial was conducted between February and April 2007 at the University Hospital Basel, Switzerland, Division of Clinical Pharmacology and Toxicology. Georgios Imanidis, PhD, of the University of Basel was the Principal Investigator on behalf of CTI.

This study was an open, randomized, three period, single-center, dose- escalation study. Thirty-six independent human transdermal tests were conducted on male volunteers using wristwatch-like ChronoDose(TM) devices. The trial successfully proved the efficacy of the device on human subjects using its model drug compound. The dose escalation trial showed statistically significant modulation and control of the dosing profiles. Using low, medium and high concentrations, for 16 hours, the model drug permeated each subject's skin on multiple occasions, resulting in clear and distinct peaks and troughs of therapeutically effective and well-targeted blood plasma concentration levels. A non-compartmental and compartmental model based analysis of pharmacokinetics will be utilized. Local and systemic tolerability of the model drug after its transdermal administration was better than planned.

Dr. Georgios Imanidis commented, "CTI has for the first time in transdermal drug delivery history successfully completed a significant human trial with a passive, automated and programmable multiple dosing transdermal device syste
'"/>




Page: 1 2 3

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
9. Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
Post Your Comments:
(Date:7/28/2014)... July 28, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... a conference call and audio webcast to discuss financial results ... closes on Thursday, July 31, 2014 at 4:30 p.m. ET. ... Date: July 31, 2014 Time: 4:30 PM ET ... International: (678) 373-0875 A webcast replay will be ...
(Date:7/28/2014)... Calif., July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... update for the second quarter ended June 30, 2014. ... 30, 2014 was $7.3 million, compared to $8.3 million for ... is a direct result of a decrease in interest expense ... the six months ended June 30, 2014 was $15.2 million, ...
(Date:7/28/2014)... Corporation (NASDAQ: LMNX ) today announced financial ... Financial and operating highlights include the following: ... 2 percent increase over the second quarter of 2013. ... a 9 percent increase over the second quarter of ... analyzers, which included 148 LX systems, 96 MAGPIX systems, ...
Breaking Medicine Technology:Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17
... PRGO ; TASE) today announced results for its ... and CEO Joseph C. Papa commented, "We are very pleased ... contributors to this strong performance were $44 million of new ... segments and another solid quarter in Nutritionals. In Consumer Healthcare, ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... at the Bank of America Merrill Lynch Healthcare conference in Las ... Vegas, NV Presentation date: Tuesday May 10, 2011 ... A live webcast and 30-day archive of this presentation will ...
Cached Medicine Technology:Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 2Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 3Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 4Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 5Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 6Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 7Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 8Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 9Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 10Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 11Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 12Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 13Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 14Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 15Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 16Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 17Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 18
(Date:7/28/2014)... Cancer cells are gluttons. We have long known that ... became clear that some tumor cells are also characterized ... unlikeliness to join in an ordered set. Researchers are ... metastasis. , At EPFL, Etienne Meylan,s research team was ... for sugar and mesenchymal behavior result from the ...
(Date:7/28/2014)... Ticket Down is a reputable source ... between Manchester City and Liverpool FC at Yankee Stadium ... countless big events since it opened several years ago. It ... Yankee Stadium, however, it has been a popular destination for ... , The Yankees Stadium is the home of the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3
... increase lowers chance of hospitalization or death , ... heart failure, high doses of the drug losartan, an ... and death, a new study shows. , Though ARBs ... study focused on whether dose level makes a difference. ...
... what women should do about the new guidelines, , WEDNESDAY, ... force recommended that women wait until they,re 50 to get ... swift. , Critics such as the American Cancer Society vowed ... age 40 for women of average risk. The American ...
... ... the AnnArbor.com Business Review awarded the company top honors in the Healthcare category during ... ongoing commitment to the local community and recent completion of a $3.6 million expansion ... ...
... Apieron, Inc. has asked the court presiding over ... to raise additional grounds for invalidating Aerocrine,s broadest patent ... , In its motion, Apieron alleges that recently obtained ... Alving, Jan Lundberg, and Edward Weitzberg, inventors named on ...
... , SYDNEY, Nov. 18 Members of the Church ... Ambassadors were out in force Sunday, November 15, distributing thousands ... purpose: to inform kids of the truth about drugs so ... a new drug called Mephedrone, or "MM-Cat," that Sydney students ...
... ... a KTRK-TV, a local television news affiliate, is bringing to light a new technique ... the recovery process and the aesthetic results for patients who undergo surgical treatment for ... ...
Cached Medicine News:Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:Mammography: What to Do Now? 2Health News:Mammography: What to Do Now? 3Health News:Mammography: What to Do Now? 4Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 2Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 3Health News:Scientology Volunteers Attack Drug Abuse in Sydney 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: